Janssen Inc. v. Apotex Inc., 2022 FC 995 (Macitentan*)
Justice Pallotta - 2022-05-20
Read full decision. Automatically generated summary:
Judgment: This Court declares that the making, constructing, using or selling of APO-MACITENTAN 10mg film-coated tablets by Apotex in accordance with its Abbreviated New Drug Submission No. 236527 (Apotex Product) would infringe claims 1-5 and 21-31 of Canadian Patent No. 2,659,770 indirectly, by inducing infringement.
Decision relates to:
- T-555-20 - JANSSEN INC. ET AL. v. APOTEX INC.
- A-131-22(2023 FCA 220) - which is an appeal from this decision